北极治疗法筹集了26.5百万欧元,用于促进痴呆症和皮肤疾病药物试验。 Arctic Therapeutics raises €26.5M to advance dementia and skin disease drug trials.

冰岛一家制药公司北极治疗公司获得2 650万欧元的资金,用于推进对痴呆症和皮肤炎症的治疗。 Arctic Therapeutics, an Icelandic drug company, secured €26.5 million in funding to advance its treatments for dementia and inflammatory skin diseases. 这些资金将支持AT-001和AT-004的临床试验,前者针对罕见形式的痴呆症,后者针对丙烯等情况。 The funds will support clinical trials for AT-001, which targets rare forms of dementia, and AT-004, aimed at conditions like acne. 这一投资加快了对潜在新疗法的研究,给全世界患者带来更好的治疗希望。 This investment accelerates research into potential new therapies, bringing hope for better treatments for patients worldwide.